In one paragraphArticle in Immune network, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Haydn E RichCenter for Metabolic and Degenerative Diseases, Brown Foundation Institute of Molecular Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX 77030, USA.ORCID https://orcid.org/0009-0006-8360-293X Yi-Dong LiCenter for Immunology and Autoimmune Diseases, Brown Foundation Institute of Molecular Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX 77030, USA.ORCID https://orcid.org/0009-0000-3482-2553 Kathryn D HokCenter for Metabolic and Degenerative Diseases, Brown Foundation Institute of Molecular Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX 77030, USA.ORCID https://orcid.org/0009-0008-8335-7617 Stacey L Mueller-OrtizCenter for Immunology and Autoimmune Diseases, Brown Foundation Institute of Molecular Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX 77030, USA.ORCID https://orcid.org/0009-0009-1530-3550 Aleksey Y DomozhirovCenter for Immunology and Autoimmune Diseases, Brown Foundation Institute of Molecular Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX 77030, USA.ORCID https://orcid.org/0009-0000-9851-3952 Anthony ShadidCenter for Metabolic and Degenerative Diseases, Brown Foundation Institute of Molecular Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX 77030, USA.ORCID https://orcid.org/0009-0000-6282-1427 Kristin L Eckel-MahanCenter for Metabolic and Degenerative Diseases, Brown Foundation Institute of Molecular Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX 77030, USA.ORCID https://orcid.org/0000-0001-8201-1675 Marcos I RestrepoVA-San Antonio Geriatric Research Education and Clinical Center (GRECC)-South Texas Veterans Health Care System Audie L. Murphy Division, UTHealth San Antonio, San Antonio, TX 78229, USA.ORCID https://orcid.org/0000-0001-9107-3405 Pooja ShivshankarCenter for Metabolic and Degenerative Diseases, Brown Foundation Institute of Molecular Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX 77030, USA.ORCID https://orcid.org/0000-0002-5040-6805 Funding
MURINE COMPLEMENT C5 DEFICIENCY--MOLECULAR BASISR01AI025011 · NIAID · WASHINGTON UNIVERSITY · PI WETSEL, RICK A. · 1987 to 2017
$4.6MComplement and Circadian Interactions in Inflammation and ImmunityR01AI158694 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MAHAN, KRISTIN ECKEL, SHIVSHANKAR, POOJA · 2021 to 2025
$1.9MNIAID NIH HHS R01 AI025011NIAID NIH HHS R01 AI158694
6 · The paper itselfAbstract
The lymphatic system is a highly branched endothelial tubular network that facilitates the migration of immune cells from the peripheral tissues to lymph nodes (LNs) and other lymphoid organs. Complement factors are essential for innate and adaptive immune functions. Complement anaphylatoxin C5a is crucial in vascular endothelial cell activation and lymphocyte polarization. Understanding the impact of C5a and its cognate receptor C5ar1 signaling on lymphatic function could provide new insights into the mechanisms of immune dysregulation observed in chronic inflammatory diseases. We demonstrate that acute C5a challenge in wildtype C57B6/J mice significantly reduced lymph propulsion compared to their C5ar1-deficient counterparts. C5ar1-dependent attenuation of lymph propulsion with LPS challenge corroborated with significantly increased endothelial-derived inducible nitric oxide synthase (iNOS) expression. C5ar1-iNOS axis modulated T helper cell polarization towards Cd4
Indexed as
AnaphylatoxinsC5a receptor 1 signalingCD146-vimentin interactionCytokinesEndothelial functionEndothelial-T cell interactionLymphatic vesselsNitric oixide synthase type II
Identifiers
PMID42109609
PMCPMC13150431
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390